|
<< BACK TO
SEVENTH GAVI BOARD MEETING
Seventh GAVI Board Meeting, Stockholm, 11 March 2002
4. Guidelines for use of Window #3 of the Vaccine Fund
Click here to download paper [MS Word,
77kb]
Discussion
-
The GAVI research agenda needs to be focused on implementation: what
kind of research is required to get more vaccines to more children in
the shortest time?
-
As we advocate for the development of new vaccines it will be
important to consider how vaccine standards have changed ' even in the
last 20 years ' and whether today's regulatory hurdles are too high to
encourage new product development. This may warrant further
exploration and discussion at a future meeting.
-
The involvement of developing country researchers and manufacturers is
essential in the GAVI research agendas.
DECISIONS
The Board:
4.1. Took note of the proposal to establish Accelerated Development and
Introduction Plans (ADIPs) to better address GAVI priorities to speed
development and introduction of pneumococcal and rotavirus vaccines, and
new technologies and management strategies to improve immunization
coverage. The meningococal vaccine is not included as this project is
already managed through the Meningococcal Vaccine Program (MVP).
4.2. Requested more in-depth information on the management structure and
arrangements for accountability for the proposed ADIPs, and on the
selection process for the ADIP managers.
4.3. Agreed that more work needs to be done to elucidate the ADIP
process, particularly for managing R&D work once it has been
commissioned, how developing countries will be involved, and how it will
incorporate the efforts of all of the relevant GAVI task forces, before
guidelines for using Vaccine Fund resources for R&D can be approved.
4.4. Will review the ADIPs for the pneumococcal and rotavirus vaccines
at its next Board meeting in June and consider the need for opening
Window 3 of the Vaccine Fund to support the implementation of these
plans.
<< BACK TO
SEVENTH GAVI BOARD MEETING
|